Glioblastoma Multiforme is a fast-growing type of central nervous system tumor that forms from glial (supportive) tissue of the brain and spinal cord and has cells that look very different from normal cells. Glioblastoma multiforme usually occurs in adults and affects the brain more often than the spinal cord. Also called GBM, glioblastoma, and grade IV astrocytoma.
Scientists at Virginia Commonwealth University believe they have uncovered an "Achilles heel" of glioblastoma multiforme, the most common and deadly form of brain cancer.
Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median life expectancy for patients diagnosed with the disease is less than 15 months.
Precision cancer treatment relies on obtaining molecular information about the tumor to guide effective treatment decisions.
Glioblastoma multiforme (GBM) is an incredibly deadly brain cancer and presents a serious black box challenge. It's virtually impossible to observe how these tumors operate in their natural environment and animal models don't always provide good answers.
A large European research collaboration is bringing new technology to bear to combat two of the most aggressive brain cancers.
Glioblastoma multiforme is the most common and aggressive primary brain tumor and has one of the worst survival rates of all cancers.
A drug that spurs cancer cells to self-destruct has been cleared for use in a clinical trial of patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, an aggressive late-stage cancer of the brain.
Several patients with recurring glioblastoma, a deadly brain cancer, survived for more than a year in a clinical trial believed to be the first to use comprehensive DNA and RNA sequencing of a patient's tumor to inform treatment for these patients in real-time.
Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the world's more diverse populations, according to a study led by the Translational Genomics Research Institute, an affiliate of City of Hope, and the Keck School of Medicine of the University of Southern California.
From Sherlock Holmes to Agatha Christie, arsenic is often the poison of choice in popular whodunits. But in ultra-low dosage, and in the right form, this naturally occurring chemical element can be a potent force against cancer.
Pioneering charity Brain Tumour Research has been awarded a £150,000 grant over three years by London Freemasons.
Understanding the mechanisms that give cancer cells the ability to survive and grow opens the possibility of developing improved treatments to control or cure the disease.
Glioblastoma multiforme (GBM), an extremely aggressive brain cancer, is a very complex disease. It is characterized by a fast-growing tumor in the brain composed of many subpopulations of cells, including glioblastoma stem cells, which play a crucial role in glioblastoma initiation, expansion and therapy-resistance.
SCIENTISTS in the UK and India have observed a "significant" lack of 'editing' in microRNAs in brain tissue of brain cancer patients.
Researchers from the Cancer Science Institute of Singapore at the National University of Singapore have discovered that the BCL6 protein could potentially be used as a marker to predict clinical outcomes of patients suffering from Glioblastoma Multiforme, the most malignant cancer of the brain.
The first drug using spherical nucleic acids to be systemically given to humans has been developed by Northwestern University scientists and approved by the Food and Drug Administration as an investigational new drug for an early-stage clinical trial in the deadly brain cancer glioblastoma multiforme.
Detecting brain tumors at the earliest possible stage and eliminating them before seizures begin might be possible one day, according to research by scientists at Baylor College of Medicine and Texas Children's Hospital.
The U.S. Food and Drug Administration (FDA) in less than a 15-month period has granted a new and updated 510(k) clearance for two patented technologies made by NICO Corporation that are used in a new approach for brain surgery.
A study led by scientists at the Translational Genomics Research Institute has identified "a potent inhibitory compound" in the elusive hunt for an improved treatment against glioblastoma, the most common and deadly type of adult brain cancer.
"Devastating" and "dismal." That's how leading researchers describe the present outlook for malignant brain tumors. The median survival rate for patients with glioblastoma multiforme, or GBM, is a mere 14.2 months.